Subjects | 77 | 15 (19) | 62 (81) | |
Male | 45 (58) | 11 (73) | 34 (55) | 0.192 |
Age years | 62 (49–67) | 54 (48–64) | 62 (51–70) | 0.142 |
Adult-onset (age >18 years) asthma | 42 (55) | 6 (40) | 36 (58) | 0.207 |
Atopy | 36 (47) | 9 (60) | 27 (44) | 0.252 |
BMI kg·m−2 | 25±3 | 26±3 | 25±3 | 0.398 |
Pack-years | 0 (0–2) | 0 (0–0) | 0 (0–2.5) | 0.351 |
Fluticasone equivalent mg | 500 (500–1000) | 500 (500–500) | 500 (500–1000) | 0.058 |
OCS-dependent | 10 (13) | 0 (0) | 10 (16) | 0.095 |
OCS dose mg | 0 (0–10) | 0 (0–0) | 0 (0–10) | 0.099 |
Pulmonologist visits in preceding year | 2 (1–3) | 2 (1–3) | 2 (2–4) | 0.031 |
≥1 ER visit in preceding year | 11 (14.3) | 3 (20) | 8 (12.9) | 0.484 |
≥1 admission in preceding year | 8 (10.4) | 1 (6.7) | 7 (11.3) | 0.601 |
Blood eosinophils ×109·L−1 | 0.2 (0.1–0.4) | 0.2 (0.1–0.4) | 0.2 (0.1–0.4) | 0.974 |
Blood neutrophils ×109·L−1 | 4.4 (3.5–5.7) | 4.3 (3.2–5.2) | 4.5 (3.6–6.0) | 0.210 |
Total IgE, kU·L−1 | 110 (35–287) | 118 (20–491) | 105 (39–285) | 0.657 |
FeNO ppb | 27 (19–54) | 24 (19–53) | 27 (20–55) | 0.699 |
FEV1 % pred | 68 (56–80) | 78 (73–86) | 66 (56–79) | 0.017 |
FVC % pred | 102±19 | 108±19 | 100±18 | 0.156 |
FEV1/FVC % pred | 70 (63–76) | 72 (64–79) | 69 (63–76) | 0.241 |
TLC % pred | 110±14 | 110±16 | 109±14 | 0.855 |
RV/TLC % pred | 113±25 | 99±20 | 117±25 | 0.010 |
FRC/TLC % pred | 113±16 | 101±18 | 115±14 | 0.001 |
IC baseline L | 2.86 (2.25–3.77) | 3.32 (2.99–3.90) | 2.79 (2.13–3.77) | 0.045 |
ΔIC L | 0.47 (0.31–0.68) | 0.16 (−0.01–0.26) | 0.55 (0.37–0.71) | <0.001 |
ΔIC % | 17.8 (12–25) | 4.8 (−0.51–7.65) | 19.5 (14.3–25.9) | <0.001 |